tularensisoligosaccharides of defined OAg repeat length while molecular rulers in competition enzyme-linked immunosorbent assay (ELISA), the epitope targeted from the terminal-binding MAb Abdominal63 was shown to span a single tetrasaccharide repeat (32), whereas the epitope targeted by Abdominal52 was shown to span two tetrasaccharide repeats (33). a mouse model to discover protecting B-cell epitopes for tularemia vaccines or prophylactic/restorative antibodies, and they present a general strategy for interrogating the antibody reactions of individuals and vaccinees to microbial carbohydrate epitopes that have been characterized in experimental animals. == Intro == Francisella tularensis, the Gram-negative bacterium that causes tularemia, is considered a potential bioterrorism danger due to JNJ-42165279 its low infectivity dose and the high morbidity and mortality of respiratory disease (14). An attenuated type B live vaccine strain (LVS) is partially protecting against infection from the highly virulent type AF. tularensisbut is not currently licensed due to security issues (5,6). The development of alternate vaccines and of immunotherapeutics must take into account both the T- and B-cell parts that contribute to immune safety againstF. tularensis(712). Antibodies to theF. tularensislipopolysaccharide (LPS) have been shown to be protecting against respiratory tularemia in BALB/c, C3H/HeN, C57BL/6, and C57BL/10 mice, andF. JNJ-42165279 tularensisantibodies, most of which are directed to LPS, have been shown to ameliorate tularemia in humans (1322). Lipopolysaccharide (LPS), the main component of theF. tularensisouter membrane, is definitely identical in the type A and BF. tularensisstrains (2327). It is composed of lipid A, a core oligosaccharide (C, primarily Hex4HexNAcKdo), and anO-polysaccharide (O antigen [OAg]) (2329). The OAg consists of various numbers of the tetrasaccharide repeat [2)–d-4,6-dideoxy-4-formamido-d-glucose(14)–d-2-acetamido-2-deoxy-d-galacturonamide(14)–d-2-acetamido-2-deoxy-d-galacturonamide(13)–d-2-acetamido-2,6-dideoxy-d-glucose(1] (Qui4NFm-GalNAcAN-GalNAcAN-QuiNAc or ABCD), with Qui4NFm in the nonreducing end (2328). TheF. tularensiscapsular polysaccharide also consists of OAg (28,29). We previously reported that anti-F. tularensisLPS mouse monoclonal antibodies (MAbs) can confer survival to BALB/c mice infected intranasally (i.n.) with an normally lethal dose KSR2 antibody of LVS (30). Subsequently, we found that the anti-LPS MAbs target OAg, and we characterized two types ofF. tularensisOAg epitopes: repeating internal epitopes targeted by the vast majority of mouse OAg MAbs and a nonoverlapping less immunogenic unique epitope in JNJ-42165279 the nonreducing end (31). The two types of MAbs are distinguished by their Western blot reactivities with LPS, where terminal binders react equally with short and long chains, all of which have one nonreducing-end epitope, whereas internal binders show improved reactivity with increasing LPS chain size (31,32). Despite the much higher quantity of epitopes per OAg chain that can be engaged by the internal binders, all four available terminal-binding MAbs have higher bivalent avidity than the most potent internal-binding MAb, Ab52 (32), and higher agglutination titers (31,32). UsingF. tularensisoligosaccharides of defined OAg repeat size as molecular rulers in competition enzyme-linked immunosorbent assay (ELISA), the epitope targeted from the terminal-binding MAb Ab63 was shown to span a single tetrasaccharide repeat (32), whereas the epitope targeted by Ab52 was shown to span two tetrasaccharide repeats (33). The X-ray crystal constructions of the Fab fragments (the light chain plus the variable and first constant domains of the weighty chain) of Ab52 and of a closely related clonal variant of Ab63 were identified, and a 2-repeat computational model of theF. tularensisOAg chain was docked into the binding sites, guided from the immunochemical constraints (32,34). These studies revealed the binding site of Ab63 is definitely a small cavity that can accommodate the 1st and part of the second terminal sugars residues of OAg with limited envelopment of the terminal Qui4NFm sugars by aromatic amino acids, which may clarify the higher affinity of terminal-binding MAbs (32). The binding site of Ab52 is definitely a large groove having a central pocket that accommodates a V-shaped epitope consisting of six sugars residues that span two tetrasaccharide repeat devices, BCDABC (34). Ab63 and Ab52 were shown to prolong the survival of and reduce blood bacterial burden in BALB/c mice infected i.n. with the highly virulentF. tularensistype A strain SchuS4 (32,33). To determine if humans create both terminal- and internal-binding antibodies in response to illness withF. tularensis, we tested 18 blood serum samples from 11 tularemia individuals for their ability to compete with Ab63 or Ab52 for antigen binding. We display with this study that all sera have both Ab63- and Ab52-inhibitory activities and that the inhibitory antibodies comprise IgG, IgM, and IgA. == MATERIALS AND METHODS == == Human being sera. == EighteenF. tularensis-positive blood serum samples from 11 individuals, in.